| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C M McLaughlin, P A Harnedy-Rothwell, R A Lafferty, S Sharkey, V Parthsarathy, P J Allsopp, E M McSorley, R J FitzGerald, F P M O'Hart. Macroalgal protein hydrolysates from Palmaria palmata influence the 'incretin effect' in vitro via DPP-4 inhibition and upregulation of insulin, GLP-1 and GIP secretion. European journal of nutrition. vol 60. issue 8. 2021-11-09. PMID:34081167. |
macroalgal protein hydrolysates from palmaria palmata influence the 'incretin effect' in vitro via dpp-4 inhibition and upregulation of insulin, glp-1 and gip secretion. |
2021-11-09 |
2023-08-13 |
Not clear |
| Ajay Manaithiya, Ozair Alam, Vrinda Sharma, Mohd Javed Naim, Shruti Mittal, Imran A Kha. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus. Bioorganic chemistry. vol 113. 2021-10-25. PMID:34048996. |
gpr119 monitors physiological mechanisms that enhance homeostasis of glucose, such as glucose-like peptide-1, gastrointestinal incretin hormone levels, pancreatic beta cell-dependent insulin secretion and glucose-dependent insulinotropic peptide (gip). |
2021-10-25 |
2023-08-13 |
Not clear |
| Beata Lecka-Czerni. Safety of Anti-Diabetic Therapies on Bone. Clinical reviews in bone and mineral metabolism. vol 11. issue 1. 2021-10-21. PMID:23543908. |
indeed, bone and energy homeostasis are under the control of the same regulatory factors, including insulin, peroxisome proliferator activated receptor gamma (pparγ), gastrointestinal hormones such as glucose inhibitory protein (gip) and glucagon inhibitory peptide (glp), and bone derived hormone osteocalcin. |
2021-10-21 |
2023-08-12 |
Not clear |
| Michael A Nauck, Daniel R Quast, Jakob Wefers, Andreas F H Pfeiffe. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, obesity & metabolism. vol 23 Suppl 3. 2021-10-18. PMID:34310013. |
the incretin hormones glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) have their main physiological role in augmenting insulin secretion after their nutrient-induced secretion from the gut. |
2021-10-18 |
2023-08-13 |
human |
| Michael A Nauck, Daniel R Quast, Jakob Wefers, Andreas F H Pfeiffe. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, obesity & metabolism. vol 23 Suppl 3. 2021-10-18. PMID:34310013. |
gip and glp-1 have additive effects on insulin secretion. |
2021-10-18 |
2023-08-13 |
human |
| Michael A Nauck, Daniel R Quast, Jakob Wefers, Andreas F H Pfeiffe. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, obesity & metabolism. vol 23 Suppl 3. 2021-10-18. PMID:34310013. |
gip, but not glp-1 increases triglyceride storage in white adipose tissue not only through stimulating insulin secretion, but also by interacting with regional blood vessels and gip receptors. |
2021-10-18 |
2023-08-13 |
human |
| Jason A West, Anastasia Tsakmaki, Soumitra S Ghosh, David G Parkes, Rikke V Grønlund, Philip J Pedersen, David Maggs, Harith Rajagopalan, Gavin A Bewic. Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism. PloS one. vol 16. issue 3. 2021-10-15. PMID:33788878. |
thus, the co-administration of both a gipr antagonist with a glp1 agonist uncovers interesting beneficial effects on measures of insulin sensitivity, circulating lipids and certain adipose stores that seem influenced by the degree or nature of gip receptor antagonism. |
2021-10-15 |
2023-08-13 |
mouse |
| Débora Villaño, Pilar Zafrilla, Cristina García-Viguera, Raúl Domínguez-Perle. A UHPLC/MS/MS method for the analysis of active and inactive forms of GLP-1 and GIP incretins in human plasma. Talanta. vol 236. 2021-10-13. PMID:34635208. |
glucagon-like peptide (glp)-1 and the glucose-dependent insulinotropic peptide (gip) are incretin hormones that regulate the nutrient-stimulated insulin secretion from pancreatic β-cells. |
2021-10-13 |
2023-08-13 |
human |
| Jens Juul Holst, Lærke Smidt Gasbjerg, Mette Marie Rosenkild. The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology. vol 162. issue 7. 2021-10-07. PMID:33782700. |
the incretin effect-the amplification of insulin secretion after oral vs intravenous administration of glucose as a mean to improve glucose tolerance-was suspected even before insulin was discovered, and today we know that the effect is due to the secretion of 2 insulinotropic peptides, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1). |
2021-10-07 |
2023-08-13 |
Not clear |
| Jens Juul Holst, Lærke Smidt Gasbjerg, Mette Marie Rosenkild. The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology. vol 162. issue 7. 2021-10-07. PMID:33782700. |
the availability of antagonists for glp-1 and most recently also for gip has made it possible to directly estimate the individual contributions to postprandial insulin secretion of a) glucose itself: 26%; b) gip: 45%; and c) glp-1: 29%. |
2021-10-07 |
2023-08-13 |
Not clear |
| Nipaporn Muangchan, Benjapa Khiewvan, Saimai Chatree, Kitchaya Pongwattanapakin, Nattinee Kunlaket, Traiphop Dokmai, Reawika Chaikomi. Riceberry rice ( The British journal of nutrition. 2021-10-01. PMID:34503597. |
this study aimed to evaluate the acute effect of ingesting riceberry rice (rr) compared with that of ingesting white rice (wr) on gastric emptying rate (ger), plasma glucose and glucose-regulating hormones, including insulin, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp-1), in healthy subjects. |
2021-10-01 |
2023-08-13 |
human |
| Nipaporn Muangchan, Benjapa Khiewvan, Saimai Chatree, Kitchaya Pongwattanapakin, Nattinee Kunlaket, Traiphop Dokmai, Reawika Chaikomi. Riceberry rice ( The British journal of nutrition. 2021-10-01. PMID:34503597. |
ger was measured by scintigraphy over 240 min, and plasma concentrations of glucose, insulin, glp-1 and gip were measured at multiple time points over 180 min. |
2021-10-01 |
2023-08-13 |
human |
| Sarah L Craig, Nigel Irwin, Victor A Gaul. Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic Disorders. Clinical medicine insights. Endocrinology and diabetes. vol 14. 2021-10-01. PMID:34588834. |
recently there has been more focus directed towards the role of xenin in insulin secretion and potential for diabetes therapies, especially through its ability to potentiate the insulinotropic actions of gip as well as utilisation in dual/triple acting gut hormone therapeutic approaches. |
2021-10-01 |
2023-08-13 |
Not clear |
| Sarah L Craig, Nigel Irwin, Victor A Gaul. Xenin and Related Peptides: Potential Therapeutic Role in Diabetes and Related Metabolic Disorders. Clinical medicine insights. Endocrinology and diabetes. vol 14. 2021-10-01. PMID:34588834. |
the biological actions of xenin, including its ability to augment insulin secretion, induce satiety effects, as well as restoring gip sensitivity, earmark this peptide as an attractive antidiabetic candidate. |
2021-10-01 |
2023-08-13 |
Not clear |
| Melissa K Thomas, Amir Nikooienejad, Ross Bray, Xuewei Cui, Jonathan Wilson, Kevin Duffin, Zvonko Milicevic, Axel Haupt, Deborah A Robin. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. The Journal of clinical endocrinology and metabolism. vol 106. issue 2. 2021-09-20. PMID:33236115. |
dual gip and glp-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. |
2021-09-20 |
2023-08-13 |
Not clear |
| Sherry A Ferguson, John J Panos, Daniel Sloper, Vijayalakshmi Varma, Sumit Sarka. Alzheimer's disease: a step closer to understanding type 3 diabetes in African Americans. Metabolic brain disease. vol 36. issue 7. 2021-09-20. PMID:34021875. |
additionally, we measured levels of c-peptide, ghrelin, gastric inhibitory polypeptide (gip), glucagon-like peptide-1 (glp-1), glucagon, insulin, leptin, pai-1, resistin, and visfatin using a human diabetes 10-plex assay. |
2021-09-20 |
2023-08-13 |
human |
| Sherry A Ferguson, John J Panos, Daniel Sloper, Vijayalakshmi Varma, Sumit Sarka. Alzheimer's disease: a step closer to understanding type 3 diabetes in African Americans. Metabolic brain disease. vol 36. issue 7. 2021-09-20. PMID:34021875. |
all measures in the diabetes disease panel assay were significantly elevated in african americans: ghrelin, gip, glp-1, glucagon, insulin, and visfatin. |
2021-09-20 |
2023-08-13 |
human |
| Kim K B Clemmensen, Jonas S Quist, Dorte Vistisen, Daniel R Witte, Anna Jonsson, Oluf Pedersen, Torben Hansen, Jens J Holst, Torsten Lauritzen, Marit E Jørgensen, Signe Torekov, Kristine Færc. Role of fasting duration and weekday in incretin and glucose regulation. Endocrine connections. vol 9. issue 4. 2021-09-17. PMID:32163918. |
linear regression analysis was applied to study the associations of overnight fasting duration and day of the week with glucose, insulin, glucagon, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp-1) responses to an ogtt. |
2021-09-17 |
2023-08-13 |
human |
| Yuki Murata, Norio Harada, Shigenobu Kishino, Kanako Iwasaki, Eri Ikeguchi-Ogura, Shunsuke Yamane, Tomoko Kato, Yoshinori Kanemaru, Akiko Sankoda, Tomonobu Hatoko, Sakura Kiyobayashi, Jun Ogawa, Akira Hirasawa, Nobuya Inagak. Medium-chain triglycerides inhibit long-chain triglyceride-induced GIP secretion through GPR120-dependent inhibition of CCK. iScience. vol 24. issue 9. 2021-09-03. PMID:34466786. |
long-chain triglycerides (lcts) intake strongly stimulates gip secretion from enteroendocrine k cells and induces obesity and insulin resistance partly due to gip hypersecretion. |
2021-09-03 |
2023-08-13 |
mouse |
| Ben Jones, Emma Rose McGlone, Zijian Fang, Phil Pickford, Ivan R Corrêa, Atsuro Oishi, Ralf Jockers, Asuka Inoue, Sunil Kumar, Frederik Görlitz, Chris Dunsby, Paul M W French, Guy A Rutter, Tricia Tan, Alejandra Tomas, Stephen R Bloo. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors. The Journal of biological chemistry. vol 296. 2021-08-20. PMID:33268378. |
moreover, in wildtype cells, "biased" glp-1, gcg, and gip analogs with selective reductions in β-arrestin-2 recruitment led to reduced receptor endocytosis and increased insulin secretion over a prolonged stimulation period, although the latter effect was only seen at high agonist concentrations. |
2021-08-20 |
2023-08-13 |
Not clear |